Genovis AB is primarily active in the biotechnology and life sciences industry.

The main competitors of Genovis AB in the market include Abcam plc, Merck KGaA, and Thermo Fisher Scientific Inc.

Genovis AB, a renowned biotechnology company, has an interesting history and background. Established in 1999 and headquartered in Lund, Sweden, Genovis specializes in innovative solutions for the development and production of enzymes and enzyme-based products. They possess a deep expertise in protein engineering and biomarker identification, offering cutting-edge tools and technologies for researchers in the fields of drug discovery, diagnostics, and therapeutic development. Genovis is committed to providing advanced solutions, such as their well-known enzyme portfolio, GlyCLICK™ antibody labeling kits, and biomarker assay development services. Continuously expanding and emphasizing collaborations with scientific partners globally, Genovis AB remains at the forefront of biotechnology advancements.

Genovis AB has achieved several significant milestones in its history. One of the most notable accomplishments was the development of innovative enzyme technologies for the biopharmaceutical industry. The company's unique products, such as SmartEnzymes™, have revolutionized the field by enabling efficient drug development and production processes. Genovis AB has also established successful collaborations with leading pharmaceutical companies, further strengthening its position in the market. With its continuous dedication to research and development, Genovis AB continues to make breakthroughs in enzymology, delivering cutting-edge solutions for the biotech sector.

Genovis AB is primarily present in multiple countries and regions. Its global presence spans across North America, Europe, Asia-Pacific, and other international markets. With a strong foothold in Sweden, Genovis AB has expanded its operations across various European countries, such as Germany, France, and the United Kingdom. Moreover, the company has also established significant market presence in the United States and Canada, highlighting its commitment to the North American region. Additionally, Genovis AB is actively engaged in serving customers in the Asia-Pacific region, including countries like China, Japan, and Australia.

Genovis AB represents values of innovation, expertise, and partnership in the field of biotechnology. The company is committed to providing cutting-edge solutions and technologies for protein research and drug development. With a strong focus on customer satisfaction, Genovis AB embraces a collaborative approach, working closely with researchers, pharmaceutical companies, and academic institutions. By offering advanced enzymes and tools for protein analysis and engineering, Genovis AB aims to facilitate breakthrough discoveries and enhance therapeutic development processes. Through continuous product improvement, knowledge sharing, and ethical practices, Genovis AB strives to make a positive impact in the scientific community and contribute to human health and well-being.

Analysts currently set an average price target of 35,70 SEK for the Genovis stock (median: 30,60 SEK), implying +81,2 % versus the latest price. The consensus is based on 8 analyst ratings.

Genovis Analyytikkojen kursstavoitteet 2026

8 analysts currently rate the Genovis stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genovis to generate revenue of 145,80 M SEK and earnings per share of 0,35 SEK.

Genovis Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Genovis share trades at 1,81 EUR (19,80 SEK).

The Genovis share (GENO.ST) is listed on 4 stock exchanges, including: Frankfurt (5GV.F), München (5GV.MU).

Genovis AB is a leading biotech company that develops innovative solutions in the field of biology and proteomics. The company was founded in 1999 and is headquartered in Lund, Sweden. The business model of Genovis is divided into three main divisions: Enzymes, Tools, and Services. The Enzyme division focuses on the development and production of recombinant proteases, including glycosidases, hydrolases, proteases, and peptidases. These enzymes play an important role in many applications in proteomics and the production of biotherapeutics, such as glycan synthesis, peptide sequencing, and therapeutic protein production. Genovis' Tools division offers a wide range of tools and accessories for proteomics research and analysis. The products offered include antibiotics, buffer systems, reagents, and kit systems. These tools are specifically tailored to the needs of researchers and technicians working with protein characterization and analysis of biological samples. Genovis' Services division offers various services to both academic and commercial customers, including custom protease and glycosidase purification services, custom assay development and optimization, glycoconjugation services, and labeling services. The company places great emphasis on high quality and customer satisfaction. The company operates an intensive research and development department aimed at developing new and improved products and services to meet customer needs. Thanks to a strong patent and brand strategy, the company has been able to acquire various valuable patents and sell its products worldwide. An important highlight of Genovis is also its focus on sustainability and environmental protection. The company strives to minimize the environmental impact of its products and services and relies on innovative solutions to reduce its carbon footprint. Overall, Genovis AB has a strong competitive advantage in the biotech market and has a successful history of innovation and research. By combining enzymes, tools, and services, the company offers its customers a comprehensive range of products and services. Genovis' broad product range allows researchers and scientists to find the right solutions for their specific needs.

odotettu liikevaihto Genovis on 145,80 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Genovis on 23,40 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Genovis:n hinta-voitto-suhde (P/E) on tällä hetkellä 55,89. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Genovis-osakkeen arvostusta.

Genovis:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,97. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Genovis-osakkeen arvostuskennuslukuna.

Genovis:n Eulpool-laatuscore on 6/10.

Genovis:n ISIN on SE0002485979. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Genovis:n WKN on A0Q4ER. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Genovis:n ticker on GENO.ST. Tämä pörssinoteeraus käytetään Genovis-osakkeiden kauppaan pörssissä.

Genovis maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Genovis kuuluu sektoriin 'Terveydenhuolto'.

Genovis:n osingot jaetaan valuutassa SEK.